Follicular Non-Hodgkin's Lymphoma (DBCOND0060079)

Identifiers

Synonyms

Non-Hodgkin Lymphoma, Follicular Lymphoma / Follicular B-cell Non-Hodgkin's Lymphoma / Follicular B-cell non-Hodgkin lymphoma / Follicular non-hodgkin lymphoma / Nodular (follicular) lymphoma / Non Hodgkin's Follicular Lymphoma / Non-Hodgkin Lymphoma, Follicular (Nodular) / Follicular non-Hodgkin's lymphoma / Follicular lymphoma, unspecified / Follicular lymphoma / Follicular lymphomas / Nodular lymphoma (disorder) / Follicular low grade B-cell lymphoma (disorder) / Nodular lymphoma / Malignant lymphoma, centroblastic-centrocytic, follicular (disorder) / Follicular lymphoma (morphologic abnormality) / Lymphoma, Follicular / Follicular non-Hodgkin's lymphoma (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Ibritumomab tiuxetan	A monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.	B-lymphocyte antigen CD20target
Interferon alfa	An immunomodulator used to treat hepatitis B and C as well as certain types of cancer including cutaneous T-cell lymphoma and renal cell carcinoma.	Interferon alpha/beta receptor 1target Cytochrome P450 1A2enzyme
Interferon alfa-2b	A form of recombinant human interferon used to treat hepatitis B and C infection, genital warts, hairy cell leukemia, follicular lymphoma, malignant melanoma, and AIDs-related Kaposi's sarcoma.	Interferon alpha/beta receptor 2target Interferon alpha/beta receptor 1target Cytochrome P450 1A2enzyme Interferon alpha-2target
Rituximab	A monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.	B-lymphocyte antigen CD20target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05315713	An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma	Atezolizumab Mosunetuzumab Tiragolumab	treatment	1 / 2	terminated
NCT02594163	Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma	Bendamustine Brentuximab vedotin Rituximab	treatment	2	terminated
NCT05645744	Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.	MB-102 CD123 CAR	Not Available	Not Available	terminated
NCT05360238	Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL	No drug interventions	treatment	1 / 2	terminated
NCT02063685	Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma	Bendamustine Cyclophosphamide Doxorubicin Ibritumomab tiuxetan Prednisone Rituximab Vincristine	treatment	3	completed
NCT01701232	Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma	Rituximab	treatment	3	completed
NCT03113422	Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy	Venetoclax	treatment	2	completed
NCT01830465	VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma	Bortezomib Bortezomib D-mannitol Rituximab	treatment	2	completed
NCT02378337	Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality	No drug interventions	Not Available	Not Available	completed